Nutrition Journal

Table 9 WOMAC scales inter-group comparisons

From: A randomized, double blind, placebo and active comparator controlled pilot study of UP446, a novel dual pathway inhibitor anti-inflammatory agent of botanical origin

	Pain			Stiffness			Function
	30 days	60 days	90 days	30 days	60 days	90 days	30 days	60 days	90 days
UP446 500 mgs vs. UP446 250 mgs	NS*	NS	0.038	NS	NS	NS	NS	NS	NS
UP446 250 mgs vs. CELECOXIB 200 mgs	NS	NS	NS	NS	NS	NS	0.010	NS	NS
UP446 500 mgs vs. CELECOXIB 200 mgs	0.020	NS	NS	NS	NS	NS	0.015	0.043	0.039
UP446 250 mgs vs. PLACEBO	NS	NS	NS	0.000	0.027	0.015	0.010	0.043	0.039
UP446 500 mgs vs. PLACEBO	0.044	0.032	0.001	0.001	NS	0.005	0.015	0.016	0.003
CELECOXIB 200 mgs vs. PLACEBO	NS	0.009	NS	0.023	NS	NS	0.015	0.016	0.003

*NS: Not statistically significant

Back to article page

ISSN: 1475-2891

Contact us

General enquiries: journalsubmissions@springernature.com